Tellgen Corporation (China)

Tellgen Corporation, located in Shanghai, is a company specializing in the research, development, production, promotion, and sales of high-end in vitro diagnostic products. Founded in 2003, the company is headquartered in the Zhangjiang High-Tech Park in Shanghai. Their main focus is on advancing new testing technologies in the field of clinical diagnostics. In April 21, 2017, Tellgen Corporation successfully went public with the stock code 300642. The company has obtained nearly 300 medical device registration certificates. They have developed a range of products based on technologies such as flow cytometry, chemiluminescence, multiplex fluorescence PCR, and liquid chromatography-tandem mass spectrometry. These products are primarily used in tumor monitoring, autoimmune diseases, cardiovascular diseases, pathogen infections, and reproductive health. Tellgen Corporation has also partnered with Hitachi to launch the Hitachi-Tellgen compatible production line, introducing a new model for compatibility production lines in China. Tellgen Corporation adheres to the concept of "connecting global technological resources and relying on local innovation and creation." They strive to become a company with international influence in the field of life sciences and make contributions to the health industry.